Skip to content

D&A at other companies

Guardant Health logo
Guardant HealthGH
$9.44M-7.8%
Natera, Inc. logo
Natera, Inc.NTRA
$14.52M+57.2%
Revvity logo
RevvityRVTY
$105.06M+7.8%
Labcorp Holdings logo
Labcorp HoldingsLH
$173.3M+3.9%
Quest Diagnostics logo
Quest DiagnosticsDGX
$147M+5.0%
Agilent Technologies logo
Agilent TechnologiesA
$67M-8.2%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.29B+10.7%

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's D&A?
Veracyte (VCYT) reported D&A of $5.43M in Q1 2026.
How has Veracyte's D&A changed year-over-year?
Veracyte's D&A increased by 1.3% year-over-year, from $5.36M to $5.43M.
What is the long-term trend for Veracyte's D&A?
Over 4 years (2021 to 2025), Veracyte's D&A has grown at a 2.2% compound annual growth rate (CAGR), from $19.59M to $21.42M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.